I want to know if there is a guidance or regulation in UK or EU which defines under which circumstances a sponsor is allowed to transfer IMP from one site to another during the course of a clinical trial. If so can anyone please provide a link to such a guidance or regulation. If there is no guidance or regulation, how can a sponsor define such a site to site transfer of IP in its SOPs.